2022未來科技獎、第 16屆國家新創獎-「類風濕性關節炎的一種新穎性單株抗體」

生物製劑(bDMARD)問世已大幅改善類風濕關節炎的治療效果，然而仍有30%患者治療反應不理想。因此，我們發展不同標的模式的生物製劑(BR2)用於治療類風濕關節炎。類風濕性關節炎動物模型結果顯示BR2治療具有劑量依賴性，改善關節指數及踝圍大小、減緩發炎、滑膜增生、改善關節間隙及軟骨生成。此單株抗體提供新的作用機轉用於治療類風濕關節炎。

The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) has significantly improved the treatment outcomes of rheumatoid arthritis (RA). However, there still exists a subgroup of patients, approximately 30%, who do not respond satisfactorily to treatment. Therefore, we have developed a novel biologic agent targeting a different pathway, referred to as BR2, for the treatment of RA. Results from rheumatoid arthritis animal models demonstrate that BR2 treatment exhibits dose-dependent improvement in joint indices, ankle circumference, inflammation attenuation, synovial hyperplasia reduction, joint space amelioration, and cartilage regeneration. This monoclonal antibody offers a new mechanism of action for treating rheumatoid arthritis.

團隊成員包蔡嘉哲教授、葉詠薷、吳雅雯、李偉菁